Binds Lymphokine, Cytokine, Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator Specific For A Hematopoietic Cell (e.g., Interleukin, Interferon, Erythropoietin, Etc.) Patents (Class 530/388.23)
  • Patent number: 10267807
    Abstract: The present invention relates to a method for diagnosing and/or prognosing renal dysfunction. The method comprises the steps of: —(a) determining the level of an anti-inflammatory cytokine present in a urine sample from a subject prior to physical trauma, prior to a hypotensive event, prior to sepsis, and/or prior to septic shock syndrome; (b) determining the level of the anti-inflammatory cytokine present in a urine sample from the subject following physical trauma, following or during a hypotensive event, following or during sepsis, and/or following or during septic shock syndrome; (c) calculating the difference between the level of the anti-inflammatory cytokine determined in step a) from the level of the anti-inflammatory cytokine determined in step b), and (d) providing a diagnosis and/or prognosis on the basis of a comparison between the difference calculated in step c) and the difference calculated in step c) when steps a) and b) are practiced on a control group.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: April 23, 2019
    Assignees: BELFAST HEALTH AND SOCIAL CARE TRUST, THE QUEEN'S UNIVERSITY OF BELFAST
    Inventors: William Thomas McBride, Marilyn Armstrong
  • Patent number: 9957318
    Abstract: The instant invention relates to the field of protein production and purification, and in particular to compositions and processes for controlling the amount of charge variants, aggregates, and fragments of a protein of interest, as well as host cell proteins, present in purified preparations by applying particular chromatography conditions during such protein purification.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: May 1, 2018
    Assignee: ABBVIE INC.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Christopher Chumsae
  • Patent number: 9243061
    Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: January 26, 2016
    Assignee: University of Melbourne
    Inventors: John Allan Hamilton, Andrew David Cook
  • Publication number: 20150147337
    Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 28, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
  • Patent number: 9035030
    Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: May 19, 2015
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Jochen Salfeld, Michael Roguska, Michael Paskind, Subhashis Banerjee, Daniel Tracey, Michael White, Zehra Kaymakcalan, Boris Labkovsky, Paul Sakorafas, Geertruida M. Veldman, Amy Venturini, Angela Widom, Stuart Friedrich, Nicholas W. Warne, Angela Myles, John Gawain Elvin, Alexander Robert Duncan, Elaine Joy Derbyshire, Sara Carmen, Stephen Smith, Thor Las Holtet, Sarah Leila Du Fou
  • Patent number: 9029508
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 12, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
  • Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Patent number: 9018356
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: April 28, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
  • Publication number: 20150110799
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Application
    Filed: November 12, 2013
    Publication date: April 23, 2015
    Inventors: Natarajan RAMASUBRAMANYAN, Lihua YANG, Matthew Omon HERIGSTAD, Hong YANG, Kartik SUBRAMANIAN, Xiaobei ZENG, Diane D. DONG, Wen Chung LIM, Kathreen A. GIFFORD, Zehra KAYMAKCALAN, Christopher CHUMSAE
  • Patent number: 9011858
    Abstract: Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein VH and VL domains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: April 21, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine M. Bilsborough, Shirley A. Rene
  • Patent number: 9005620
    Abstract: Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralize its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumors associated with IL-6.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: April 14, 2015
    Assignee: MedImmune Limited
    Inventors: Simon Charles Cruwys, Steven Godfrey Lane, Philip Mallinder
  • Patent number: 9005617
    Abstract: An antikine antibody binds to two, three, four, five or more CC chemokines, such as RANTES/CCL5, MIP-1?/CCL3, MIP-1?/CCL4, or MCP-1/CCL2. Methods for affinity maturation and humanization of antikine antibodies as well as the production of hybridoma cell lines producing antikine antibodies by sequential immunization are also disclosed.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: April 14, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Dan Allison, Carol Raport
  • Publication number: 20150098949
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 3, 2014
    Publication date: April 9, 2015
    Inventors: AUSTIN L. GURNEY, AARON KEN SATO, CHRISTOPHER JOHN BOND
  • Patent number: 8999330
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other cogulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: April 7, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 8992908
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat mucositis (e.g., oral mucositis) including persons on a treatment regimen with a drug or chemotherapy and/or radiation for cancer (e.g., head and neck cancer) that is associated with increased risk of mucositis, including oral mucositis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventors: Jeffrey T.L. Smith, Leon F. Garcia-Martinez, Andrew L. Feldhaus
  • Patent number: 8992920
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as anti-IL-6 antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat rheumatoid arthritis.
    Type: Grant
    Filed: November 23, 2011
    Date of Patent: March 31, 2015
    Assignee: Alderbio Holdings LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 8992913
    Abstract: The disclosure provides improved neutralizing anti-GDF-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-GDF-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.
    Type: Grant
    Filed: June 12, 2013
    Date of Patent: March 31, 2015
    Assignee: Pfizer Inc.
    Inventors: Michelle M. Mader, James R. Apgar, Kevin D. Parris
  • Patent number: 8992922
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: March 31, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Patent number: 8986692
    Abstract: The present invention provides an anti-VEGF monoclonal antibody, which has the variable region of heavy chain comprising the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, and/or the variable region of light chain comprising the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6. The antibody can be produced by the cell line with the preservation number of CGMCC NO. 3233. The invention also provides the use of said antibody for the manufacture of medicaments for the treatment of a disease that is relevant to VEGF, wherein further provided are pharmaceutical composition, agents, kits and chips comprising said antibody, as well as the cell line with the preservation number of CGMCC NO. 3233.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: March 24, 2015
    Assignees: Jiangsu Simcere Pharmaceutical R & D Co., Ltd., Apexigen Inc.
    Inventors: Pierre Li, Yaohuang Ke, Yongke Zhang, Weimin Zhu, Guoliang Yu, Fanxin Ma, Xin Fan
  • Patent number: 8986685
    Abstract: Described herein are pharmaceutical compositions comprising an anti-sclerostin antibody and an inhibitor of bone resorption.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: March 24, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Mary E. Brunkow, David J. Galas, Brian Kovacevich, John T. Mulligan, Bryan W. Paeper, Jeffrey Van Ness, David G. Winkler
  • Patent number: 8987418
    Abstract: Engineered multivalent and multispecific binding proteins that bind IL-1? and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: March 24, 2015
    Assignee: AbbVie Inc.
    Inventors: Tariq Ghayur, JiJie Gu, Maria Harris, Carrie Goodreau, Sonal Saluja
  • Patent number: 8980257
    Abstract: It has been found out that among antibodies showing reactivity with wild type TGF-?, antibodies less reactive with G79A-substituted TGF-? have an excellent growth-suppressing effect on cancer cells having a mutated Ras gene. Further, it has been found out that most of these antibodies have an activity of inhibiting EGFR tyrosine phosphorylation and/or an induction-suppressing activity on vascular endothelial cells.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: March 17, 2015
    Assignee: Medical & Biological Laboratories Co., Ltd.
    Inventors: Makoto Kaneda, Yoshihiro Fujii, Yoshihiro Hayata, Yoshiro Kishi, Ichiro Yahara
  • Patent number: 8969040
    Abstract: The present invention provides an anti-BMP9 (Bone morphogenetic protein-9) monoclonal antibody or an antibody fragment thereof binding to human BMP9, a hybridoma producing the antibody or the antibody fragment, a DNA encoding the antibody or the antibody fragment, a vector comprising the DNA, a transformant obtained by introduction of the vector, a method for preparing the antibody or the antibody fragment using the hybridoma or the transformant, and a therapeutic agent comprising the antibody or the antibody fragment as an active ingredient. Further, the present invention provides a pharmaceutical composition comprising the antibody or the antibody fragment as an active ingredient for the treatment of anemia such as renal anemia, cancer anemia or the like, and a method for treating anemia such as renal anemia, cancer anemia or the like using the same.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: March 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Kiyoshi Shimizu, Yuji Yamazaki, Tsuguo Kubota, Kaname Kimura
  • Patent number: 8945561
    Abstract: Method of identifying a modulator of CD28 comprising comparing a structural model of a candidate modulator with a structural model of CD28 to thereby determine whether the modulator will bind to CD28, wherein the structural model is derived from, or comprises, structural coordinates of a crystal of: (i) CD28, (ii) a fragment of CD28, or (iii) a homolog of (i) or (ii). The crystal of CD28 in a soluble form complexed with the Fab fragment of a mitogenic (superagonistic) antibody has been obtained and used for the determination of the 3D-structure of the receptor. The application also relates to modulators of superagonistic signalling for any receptor of the CD28 family, i.e. to superagonistic antibodies and chimeric proteins thereof, and to the screening of the superagonistic modulators. In the methods of screening, the binding of the candidate modulators to a portion of the receptor proximal to the cell membrane is investigated.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: February 3, 2015
    Assignee: Isis Innovation Limited
    Inventor: Simon Davis
  • Patent number: 8945553
    Abstract: The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: February 3, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brenda L. Stevens, Alison Witte, Mark W. Rixon, Josephine M. Cardarelli, Thomas D. Kempe, Scott R. Presnell, Mohan Srinivasan, Susan C. Wong, Guodong Chen, Hui Wei, Stanley R. Krystek, Lumelle A. Schneeweis, Paul O. Sheppard, Indrani Chakraborty
  • Patent number: 8940303
    Abstract: Antigen binding proteins which bind to human IL-7 receptor (CD127) are provided. The antigen binding proteins are typically antibodies, and are useful in the treatment of diseases or disorders in humans, particularly autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: January 27, 2015
    Assignee: Glaxo Group Limited
    Inventors: Ian Kirby, Alex H. Taylor, Thomas Matthew Webb, Yu Xue
  • Patent number: 8940874
    Abstract: The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), in particular human antibodies, and antibody fragments, including those that inhibit GDF-8 activity in vitro and/or in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle or bone, or disorders of insulin metabolism.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: January 27, 2015
    Assignees: Wyeth LLC, MedImmune Limited
    Inventors: Geertruida M. Veldman, Monique V. Davies, Kening Song, Neil M. Wolfman, Kristie Grove Bridges, Anne Field, Caroline Russell, Viia Valge-Archer
  • Patent number: 8940305
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 27, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Publication number: 20150023978
    Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the C-terminal or the center region of macrophage migration inhibitory factor (MIF). These anti-MIF antibodies and antigen-binding portions thereof further inhibit human MIF biological function. The invention also relates to isolated heavy and light chain immunoglobulins derived from anti-MIF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to a method of identifying anti-MIF antibodies, pharmaceutical compositions comprising these antibodies and a method of using these antibodies and compositions for the treatment of MIF-related conditions.
    Type: Application
    Filed: January 17, 2014
    Publication date: January 22, 2015
    Applicants: Baxter International Inc., Dyax Corp., Baxter Healthcare SA
    Inventors: Randolf Kerschbaumer, Friedrich Scheiflinger, Manfred Rieger, Michael Thiele, Geert C. Mudde, Juergen Muellberg, Rene Hoet
  • Patent number: 8937158
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: January 20, 2015
    Assignee: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
  • Patent number: 8932591
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: January 13, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Publication number: 20150010544
    Abstract: A monoclonal secretory IgA antibody, which binds to and neutralizes human p40 (the p40 subunit of IL-12 and IL-23). The secretory antibody is useful in treating a variety of inflammatory conditions in humans.
    Type: Application
    Filed: December 14, 2012
    Publication date: January 8, 2015
    Inventors: Gerardus Joseph Andreas Ariaans, Frans van Dalen, Declan Thomas Nolan
  • Patent number: 8926956
    Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: January 6, 2015
    Assignees: Fundacio Privada Institut d'Investigacio Oncologica Vall d'Hebron (VHIO), Fundacio Privada Institucio Catalana de Recerca I Estudis Avancats (ICREA)
    Inventors: Joan Seoane Suarez, Judit Anido Folgueira, Andrea Saez Borderias
  • Patent number: 8926970
    Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin, e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signaling system during angiogenesis. The invention also relates to the use of regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: January 6, 2015
    Assignee: Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
    Inventors: Christof Niehrs, Olga Kazanskaya, Bisei Okawara
  • Patent number: 8921537
    Abstract: The invention herein provides isolated antibodies that bind to VEGF. The invention further provides methods of making anti-VEGF antibodies, and polynucleotides encoding anti-VEGF antibodies.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: December 30, 2014
    Assignee: Genentech, Inc.
    Inventors: Germaine Fuh, Chingwei V. Lee
  • Patent number: 8920798
    Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.
    Type: Grant
    Filed: November 20, 2012
    Date of Patent: December 30, 2014
    Assignee: Amgen Inc.
    Inventors: Huiquan Han, Hosung Min, Thomas Charles Boone
  • Patent number: 8921526
    Abstract: The present invention is directed to modified antibodies, including anti-TNF? antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The invention further provides methods of producing and using such antibodies.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 30, 2014
    Assignee: AbbVie, Inc.
    Inventors: Chris M. Chumsae, Zehra Kaymakcalan
  • Patent number: 8916158
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8916695
    Abstract: The present invention concerns antigen binding proteins and fragments thereof which specifically bind Oncostatin M (OSM), particularly human OSM (hOSM) and which inhibit the binding of OSM to the gp130 receptor but does not directly interact with site II residues. The invention also concerns a method of humanizing antibodies. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: December 23, 2014
    Assignee: Glaxo Group Limited
    Inventors: Gary Peter Bembridge, Chun-Wa Chung, Maria Feeney, Susannah Karen Ford, Ian Kirby, Ruth McAdam
  • Patent number: 8916157
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 23, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Patent number: 8911734
    Abstract: NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: December 16, 2014
    Assignee: Alderbio Holdings LLC
    Inventors: John A. Latham, Ethan W. Ojala, Jeffrey T. L. Smith, Benjamin H. Dutzar, Leon F. Garcia-Martinez
  • Patent number: 8911741
    Abstract: A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 16, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Hans-Juergen Krause, Lisa Baust, Michael Dickes
  • Publication number: 20140363422
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Application
    Filed: January 2, 2013
    Publication date: December 11, 2014
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
  • Patent number: 8906680
    Abstract: The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: December 9, 2014
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
  • Patent number: 8906373
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: December 9, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Patent number: 8907068
    Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
    Type: Grant
    Filed: May 21, 2008
    Date of Patent: December 9, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
  • Patent number: 8900578
    Abstract: The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: December 2, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Wenfeng Xu, Wayne R. Kindsvogel, Steven D. Hughes, Yasmin A. Chandrasekher
  • Publication number: 20140348848
    Abstract: This invention generally relates to a novel use of IL-1?-ligand/IL-1 receptor disrupting compounds (herein referred to also as “IL-1beta Compounds”) in a therapy preventing manifestations and especially complications leading to subsequent damages, such as vaso-occlusion, in individuals being threatened by sickle cell disease (that is, especially homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-thal gene, an individual with one sickle cell gene and one null alleleor an individual with hemoglobin SC disease).
    Type: Application
    Filed: November 29, 2012
    Publication date: November 27, 2014
    Inventor: Dhananjay Kaul
  • Publication number: 20140348847
    Abstract: The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 27, 2014
    Applicant: HOFFMAN-LAROCHE, INC.
    Inventors: Maurice Kent Gately, David Howard Presky
  • Patent number: 8895709
    Abstract: Disclosed herein are methods for the isolation and purification of antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography, preferably Protein A affinity, ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: November 25, 2014
    Assignee: AbbVie Inc.
    Inventors: Robert K. Hickman, Qing Huang, Cheryl L. Weed, Scott T. Ennis, Barbara Perilli-Palmer, Min Wan